



PRESS RELEASE 2023-05-22

## **Introducing Hamlet BioPharma to investors**

Hamlet BioPharma the innovative pharmaceutical company with a strong portfolio of projects for the treatment of cancer and infections today launches the new website introducing Hamlet BioPharma, providing a first overview of the company, recent transactions and the main projects.

A merger of HAMLET Pharma and SelectImmune Pharma was formally decided on May 17<sup>th</sup>, 2023. The decisions were taken by extra general assemblies in the respective companies. The transaction also includes the acquisition of a tuberculosis project and a collaboration agreement with Linnane Pharma. The formal process of the merger is being initiated and the process of establishing Hamlet BioPharma is estimated to complete in August.

For more information, please see [www.hamletbiopharma.com](http://www.hamletbiopharma.com)

### **For more information, please contact:**

Gabriela Godaly  
CEO (acting), SelectImmune Pharma AB  
Tel: +46 733 38 13 44  
E-mail: [gabriela.godaly@selectimmune.com](mailto:gabriela.godaly@selectimmune.com)

Catharina Svanborg  
Chairman SelectImmune Pharma AB  
Tel: +46 709 42 65 49  
E-mail: [catharina.svanborg@med.lu.se](mailto:catharina.svanborg@med.lu.se)

*SelectImmune Pharma is a pharmaceutical company whose shares are traded on the Spotlight Stock Market. The company develops new immunotherapies, which act as immune modulators and offer complements to antibiotics.*

*Bacterial infections affect large parts of the population and are becoming increasingly difficult to treat due to increasing antibiotic resistance. SelectImmune Pharma develops immunotherapies that can supplement or replace antibiotics. Urinary tract infections (UTI) are extremely common, affecting at least 50% of all women. There is an immediate need for treatment alternatives and the potential markets are very large.*